### Sodium stibogluconate

**Section:** 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.2. Antileishmaniasis medicines

**Indication:** Cutaneous leishmaniasis

**INN:** Sodium stibogluconate

**Medicine type:** Chemical agent

**List type:** Core (EML) (EMLc)

**Formulations:** Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

**EML status history:**
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1984 (TRS 722)
- Removed in 1989 (TRS 796)
- Added in 2007 (TRS 950)
- Changed in 2009 (TRS 958)
- Changed in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions

**Wikipedia:** [Sodium stibogluconate](https://en.wikipedia.org/wiki/Sodium_stibogluconate)

**DrugBank:** [Sodium stibogluconate](https://www.drugbank.ca/drugs/DB00858)

---

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule